Amazon Launches Delivery Prescription Drug Service, Amazon Pharmacy

Amazon, once an online used bookstore, has grown to dominate the retail industry, the grocery industry, and now the pharmaceutical industry. Amazon’s latest business venture, Amazon Pharmacy, spells trouble for brick-and-mortar pharmacies like Walgreens, CVS, RiteAid and more. Launched in 45 states, the service offers special benefits for prime members, as well as discounts and special relationships with healthcare plans. According to CNBC, Amazon will not share user data in compliance with HIPAA rules. As a result, the user experience will be different from what customers experience in the Amazon store.

MarketScale Radio hosts, Daniel Litwin and Tyler Kern, unpack Amazon’s latest business venture. Litwin considers what this means for small, local pharmacies, already struggling to compete with chains. Kern ponders what industries are immune to Amazon’s ability to enter and dominate, considering the company’s access to user data and convenience infrastructure.

KEY POINTS:

  • Amazon launches delivery prescription service in US market, with free delivery for Prime members.
  • Shares of walk-in pharmacies dropped at the news; how will this impact existing local pharmacies?
  • Delivery prescription delights customers wanting to avoid COVID interactions.

For the latest news, videos, and podcasts in the Retail Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @RetailMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More